Nikki C. C. Werkman

The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study

Nikki C. C. Werkman, Johanna H. M. Driessen, Coen D.A. Stehouwer et al. · Cardiovascular Diabetology · 2023 · 25 citations · Full text

Incidence, hospitalization and mortality and their changes over time in people with a first ever diabetic foot ulcer

Johan Røikjer, Nikki C. C. Werkman, Joop P. van den Bergh et al. · Diabetic Medicine · 2021 · 22 citations · Full text

Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation

Nikki C. C. Werkman, Johannes T. H. Nielen, Joop P. van den Bergh et al. · Current Drug Safety · 2020 · 16 citations · Full text

Incretin‐based therapy and the risk of diabetic foot ulcers and related events

Nikki C. C. Werkman, Johanna H. M. Driessen, Olaf H. Klungel et al. · Diabetes Obesity and Metabolism · 2024 · 13 citations · Full text

Use of sodium-glucose co-transporter 2 inhibitors, changes in body mass index and risk of fracture: A population-based cohort study

Judith van Dalem, Nikki C. C. Werkman, Joop P. van den Bergh et al. · Diabetes Research and Clinical Practice · 2022 · 12 citations · Full text